Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548 is registered in ClinicalTrials.gov with Epigenetix, Inc. as lead sponsor.

NCT NCT05488548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05488548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Lead sponsor
Epigenetix, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 21, 2022
Completion date
May 31, 2025
Enrollment
75 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, chronic myelomonocytic leukemia, myelofibrosis, nut carcinoma